Silence Therapeutics Plc
Silence Therapeutics Plc (SLN): 8 pipeline candidates · 1 upcoming catalyst · ~15 mo cash runway · 6 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
14.7 months
D/E 1.33 · 0% dilution
Lead: Phase 3
8 candidates
1 upcoming, next in ~104d
N/A
A transparent, data-derived signal for Silence Therapeutics Plcacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$321.7M
Cash
$5.7M
Quarterly Burn
$15.6M
Runway
14.7 mo
Revenue
$422K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (8 candidates)
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
50
Total value held
$39.9M
| Holder | Shares | Value |
|---|---|---|
| citadel advisors llc | 1,246,107 | $6.6M |
| millennium management llc | 1,074,191 | $5.7M |
| great point partners llc | 1,020,489 | $5.4M |
| tetragon partners gp ltd | 630,161 | $3.3M |
| 5am venture management, llc | 476,200 | $2.5M |
| jones hill capital lp | 301,604 | $1.6M |
| ubs group ag | 246,937 | $1.3M |
| boothbay fund management, llc | 209,088 | $1.1M |
| blackrock, inc. | 204,777 | $1.1M |
| bank of montreal /can/ | 202,901 | $1.1M |
Showing top 10 of 50 institutional holders of Silence Therapeutics Plc. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Silence Therapeutics Plc's pipeline?
Silence Therapeutics Plc (SLN) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Silence Therapeutics Plc's lead drug candidate?
Silence Therapeutics Plc's most advanced tracked candidate is Divesiran (Phase 2) for Polycythemia vera (PV).
What is Silence Therapeutics Plc's next catalyst?
Silence Therapeutics Plc's next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: divesiran" — expected September 30, 2026.
What is Silence Therapeutics Plc's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Silence Therapeutics Plc has approximately 14.7 months of cash runway.
What is Silence Therapeutics Plc's market capitalization?
Silence Therapeutics Plc's market capitalization is approximately $321.7M.
Get the full picture on Silence Therapeutics Plc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.